Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.
Saved in:
| Title: | Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. |
|---|---|
| Authors: | Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. motzerr@mskcc.org., Martini JF; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA., Mu XJ; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA., Staehler M; Department of Urology, University Hospital of Munich, Munich, Bavaria, 80333, Germany., George DJ; Department of Medicine, Duke Cancer Institute, Durham, NC, 27710, USA., Valota O; Global Product Development-Oncology, Pfizer S.r.L, Milan, Lombardy, 20152, Italy., Lin X; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA., Pandha HS; Department of Medical Oncology, University of Surrey, Guildford, England, GU2 7XS, UK., Ching KA; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA., Ravaud A; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, 33300, France. |
| Source: | Nature communications [Nat Commun] 2022 Oct 10; Vol. 13 (1), pp. 5959. Date of Electronic Publication: 2022 Oct 10. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36216827 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Motzer+RJ%22">Motzer RJ</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. motzerr@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Martini+JF%22">Martini JF</searchLink>; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Mu+XJ%22">Mu XJ</searchLink>; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Staehler+M%22">Staehler M</searchLink>; Department of Urology, University Hospital of Munich, Munich, Bavaria, 80333, Germany.<br /><searchLink fieldCode="AU" term="%22George+DJ%22">George DJ</searchLink>; Department of Medicine, Duke Cancer Institute, Durham, NC, 27710, USA.<br /><searchLink fieldCode="AU" term="%22Valota+O%22">Valota O</searchLink>; Global Product Development-Oncology, Pfizer S.r.L, Milan, Lombardy, 20152, Italy.<br /><searchLink fieldCode="AU" term="%22Lin+X%22">Lin X</searchLink>; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Pandha+HS%22">Pandha HS</searchLink>; Department of Medical Oncology, University of Surrey, Guildford, England, GU2 7XS, UK.<br /><searchLink fieldCode="AU" term="%22Ching+KA%22">Ching KA</searchLink>; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Ravaud+A%22">Ravaud A</searchLink>; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, 33300, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2022 Oct 10; Vol. 13 (1), pp. 5959. <i>Date of Electronic Publication: </i>2022 Oct 10. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36216827 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41467-022-33555-8 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 5959 Titles: – TitleFull: Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Motzer RJ – PersonEntity: Name: NameFull: Martini JF – PersonEntity: Name: NameFull: Mu XJ – PersonEntity: Name: NameFull: Staehler M – PersonEntity: Name: NameFull: George DJ – PersonEntity: Name: NameFull: Valota O – PersonEntity: Name: NameFull: Lin X – PersonEntity: Name: NameFull: Pandha HS – PersonEntity: Name: NameFull: Ching KA – PersonEntity: Name: NameFull: Ravaud A IsPartOfRelationships: – BibEntity: Dates: – D: 10 M: 10 Text: 2022 Oct 10 Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 2041-1723 Numbering: – Type: volume Value: 13 – Type: issue Value: 1 Titles: – TitleFull: Nature communications Type: main |
| ResultId | 1 |
